Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Telix Pharmaceuticals Provides IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting

20 Oct 2021  |  08:37:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: IPAX-1 Presentation at Congress of Neurological Surgeons

Telix Pharmaceuticals announced the first set of peer-reviewed results from the IPAX-1 Ph I/II study of TLX101 in combination with external beam radiation therapy (XRT) in recurrent glioblastoma multiforme (GBM) has been delivered as a late breaking oral presentation at the Congress of Neurological Surgeons (CNS) AFM currently taking place in Austin, Texas. The data confirms the study has met its primary objective, demonstrating safety and tolerability of TLX101 at doses tested. The results also show overall survival (OS) of 15.97 months, to date, in the second line (recurrent) GBM setting.

Please click here for full details

See more ASX300 News Announcements